赛伦生物的前世今生：2025年三季度营收1.75亿低于行业平均，净利润6421.07万高于中位数

Core Viewpoint - Sairun Bio is a leading enterprise in the field of biotoxins and biosafety drugs in China, focusing on the research, development, production, and sales of related preventive and therapeutic drugs, with strong technical barriers [1] Group 1: Business Performance - For Q3 2025, Sairun Bio reported revenue of 175 million yuan, ranking 31st out of 34 in the industry, significantly lower than the top company, Changchun High-tech, which had 9.807 billion yuan, and the second, Kanghong Pharmaceutical, with 3.624 billion yuan [2] - The net profit for the same period was 64.21 million yuan, ranking 17th in the industry, far behind the leading company, Tonghua Dongbao, which reported 1.188 billion yuan, and Changchun High-tech at 1.06 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Sairun Bio's debt-to-asset ratio was 3.14%, slightly up from 2.73% year-on-year, but significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 78.43%, a slight decrease from 78.83% year-on-year, yet still above the industry average of 70.17%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Sairun Bio decreased by 14.10% to 6,635, while the average number of circulating A-shares held per household increased by 183.92% to 16,300 [5]